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Dear Editor:
Advanced glycation end products (AGEs) are generated by 
the Maillard reaction between an aldehyde group and an 
amino group of a protein. The resulting protein degener-
ation and inflammation are linked to both aging and hy-
perglycemia1,2. Numerous carbonyl compounds are pres-
ent in vivo, including reducing sugars such as glucose or 
fructose and intermediates of glucose metabolism. Glyce-
raldehyde (GA), which is an intermediate product of both 
glycolysis and polyol metabolism, plays an important role 
in the pathogenesis of lifestyle-related diseases through the 
formation of glyceraldehyde-derived AGEs (Glycer-AGEs). 
For example, Glycer-AGEs contribute to microvascular 
complications of diabetes, i.e., retinopathy and nephrop-
athy and the malignancy of cancer via receptor for AGEs 
(RAGE) signal transduction followed by enhancement of 
intercellular ROS production3-5. It is thus expected that the 
presence of Glycer-AGEs is highly related to intracellular 
metabolism in normal skin cells. However, the presence 
of Glycer-AGEs in epidermal cells, 95% of which are kera-
tinocytes, has not been shown. We report an immunohis-
tochemical detection of Glycer-AGEs in skin using a
Glycer–AGE-specific antibody and the rates of AGE for-
mation with GA and glyoxal (GO).
Skin samples were purchased from Biopredic International 
(Saint-Grégoire, France), fixed in 4% buffered paraformalde-
hyde, and embedded in paraffin. After deparaffinization 
and antigen retrieval by heating in a microwave in 10 mM 
sodium citrate buffer (pH 6), sections were washed in 0.1% 
phosphate-buffered saline (PBS) with Tween-20 for 30 min 
and prepared for immunohistochemistry6. Nonspecific 
staining was blocked by preincubation with 1% bovine se-
rum albumin (BSA) in PBS for 1 h at room temperature.
Skin sections were incubated with the anti-Glycer–AGE
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Fig. 1. Glyceraldehyde-derived advanced glycation end products (Glycer-AGEs) in sections of human skin from the abdominal area 
of individuals 28 and 63 years of age following immunohistochemical staining with anti-Glycer-AGEs antibody. Pretreatment with 
a blocking peptide resulted in significant loss of signal. Lower panels are shown with nuclear counterstaining. Bar=100 μm.
antibody (provided by Dr. Takeuchi, Kanazawa Medical 
University) at a 1:200 dilution in 1% BSA-PBS overnight at 
4oC. For blocking peptide-treated samples, we used pri-
mary antibody incubated with a blocking peptide for 1 h 
at RT. Bound antibodies were visualized with Alexa 
488-conjugated secondary antibody at a 1:200 dilution in
1% BSA-PBS for 1 h at RT, and hoechst33258 was added
for nuclear counterstaining. All images were obtained us-
ing an IX71 microscope (Olympus, Tokyo, Japan).
GA and GO were used as the glycation inducer to assay
AGE formation in vitro. Skin was removed from 7-week-old
female hairless (Hos:HR-1) mice (Hoshino Experiment
Animal Center, Ibaraki, Japan), cleaned of subcutaneous
fat, and mounted in modified vertical diffusion cells. The
cells had an effective diffusion area of 1.77 cm2 and a re-
ceptor compartment volume of 5.0 ml. For induction of
glycation, the skin specimens were hydrated from the der-
mal side for 6 to 24 h with PBS containing either 10 mM
or 50 mM GO or GA. The receptor fluid was maintained
at 32oC, and continuously agitated with a magnetic stirrer
bar. After induction, the skin was placed on a white
board, and the color was measured using a CR-400 chro-
mameter (Konica-Minolta, Tokyo, Japan). Data were ex-
pressed in the L*a*b* color space, and the b* was used as
the yellow color value. The skin samples were then
minced in 50% methanol and sonicated. Following cen-
trifugation, AGEs were assayed in the supernatant by fluo-
rescence with excitation at 365 nm and emission at 450
nm (SpectraMax M2e; Molecular Devices, Sunnyvale, CA,
USA). To measure the modification rate of Lys, 10 mM or
50 mM of GO or GA was reacted with 10 mM of Lys in
PBS at 37oC for predetermined times. After hydrolysis in 6 
N HCl for 8 h at 110oC, the concentration of modified Lys 
was measured by JLC-500 amino acid analyzer (JEOL Ltd., 
Tokyo, Japan).
The presence of Glycer-AGEs in the epidermis and dermis 
of human skin was demonstrated by immunohistochemistry, 
but they were not found in skin pretreated with blocking 
peptides. Glycer-AGEs were detected in stratum corneum 
and viable epidermis, and to a lesser extent, dermal cells. 
No significant differences between young and old skin 
were observed (Fig. 1). 
To describe the presence of Glycer-AGEs in epidermis, 
which has a turnover rate about 1 month, we compared 
the rates of AGE formation induced by GO and GA. The 
respective amounts of AGEs induced by GA, as indicated 
by fluorescence intensity and b* value, were 3.0 and 2.2 
times higher than those of the AGEs induced by GO. 
Interestingly, the intensity and b* values induced by GO 
peaked at 6 h, whereas they continued to increase when 
induced by GA (Fig. 2A). Finally, when the basic amino 
acids Lys, Arg reacted with glycation inducer, only Lys:GA 
showed a strong yellowish tint (Fig. 2B). Consistent with 
this, the modification rate of Lys from 6 to 24 h with 50 
mM GA was greater than that of GO (26 vs. 6 nmol/h) 
(Fig. 2B).
Glycer-AGEs were present in both epidermis and dermis. 
Because of the rapid turnover rate in the epidermis, der-
mal AGEs present in long-lived substrates in the ECM such 
as collagen or elastic fiber have been the focus of research 
for a long time. Kawabata et al.7 first reported the pres-
ence of AGEs in epidermis, the major one being Nε-(car-
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Fig. 2. (A) Macroscopic view of hairless mouse skin glycated using glyoxal (GO) or glyceraldehyde (GA). Rate of increase in advanced 
glycation end product (AGE) formation indicated by fluorescence intensity (excitation: 365 nm/emission: 450 nm) and b* value. 
Glycation induced by 50 mM of GO: ○, or GA: ▲. (B) Macroscopic view of glycated amino acids before hydrolysis (6 h) and 
after hydrolysis (6, 12, 24 h). Rate of modification of Lys as determined by amino acid analysis. 
boxymethyl)lysine (CML), derived from GO and they 
found that CML was localized primarily in epidermal kera-
tin 10 and dermal ECM. However, we found that Gly-
cer-AGEs were concentrated at both epidermal and der-
mal cells. These results suggest that the accumulation of 
Glycer-AGEs in skin strongly reflects alterations in intra-
cellular metabolism caused by lifestyle-related conditions 
like hyperglycemia. Though we couldn’t detect the differ-
ence in Glycer-AGEs accumulation between young and 
aged human skin, Glycer-AGEs may contribute to skin ag-
ing via upregulation of RAGE expression in hyperglycemic 
condition8. Furthermore, the faster increase in fluo-
rescence intensity and b* value in GA- versus GO-gly-
cated skin suggests that Glycer-AGEs accumulate at early 
stages of hyperglycemia, playing a pro-inflammatory role 
via RAGE signaling and contribute to degeneration of 
proteins. In addition, we found a strong relationship be-
tween a yellowish tint of the skin and faster Lys mod-
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ification by GA. Further studies are required to elucidate 
the biological and physiological significance of Glycer-AGEs 
in skin, but our study suggests that they may influence 
normal human keratinocytes and fibroblasts by different 
mechanisms and accumulate to a different degree than 
GO-induced AGEs. 
CONFLICTS OF INTEREST
The authors have nothing to disclose.
REFERENCES 
1. Gkogkolou P, Böhm M. Advanced glycation end products:
Key players in skin aging? Dermatoendocrinol 2012;4:259-270.
2. Zhu P, Ren M, Yang C, Hu YX, Ran JM, Yan L. Involvement
of RAGE, MAPK and NF-κB pathways in AGEs-induced
MMP-9 activation in HaCaT keratinocytes. Exp Dermatol
2012;21:123-129.
3. Miura J, Yamagishi Si, Uchigata Y, Takeuchi M, Yamamoto
H, Makita Z, et al. Serum levels of non-carboxymethyllysine
advanced glycation endproducts are correlated to severity of
microvascular complications in patients with Type 1 diabetes. 
J Diabetes Complicat 2003;17:16-21.
4. Takino J, Yamagishi S, Takeuchi M. Cancer malignancy is
enhanced by glyceraldehyde-derived advanced glycation
end-products. J Oncol 2010;2010:739852.
5. Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H,
Choei H, et al. Regulation of human melanoma growth and
metastasis by AGE-AGE receptor interactions. J Invest Dermatol
2004;122:461-467.
6. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda
Y. Immunological evidence that non-carboxymethyllysine
advanced glycation end-products are produced from short
chain sugars and dicarbonyl compounds in vivo. Mol Med
2000;6:114-125.
7. Kawabata K, Yoshikawa H, Saruwatari K, Akazawa Y, Inoue
T, Kuze T, et al. The presence of N(ε)-(Carboxymethyl) lysine
in the human epidermis. Biochim Biophys Acta 2011;1814:
1246-1252.
8. Park HY, Kim JH, Jung M, Chung CH, Hasham R, Park CS, et
al. A long-standing hyperglycaemic condition impairs skin
barrier by accelerating skin ageing process. Exp Dermatol
2011;20:969-974.
